Clinical Pre-Screening Features

Massive Bio Was Named an OpenAI Select Partner for Oncology AI

Massive Bio was named an OpenAI Select Partner within the OpenAI Partner Network, expanding its work using AI for oncology clinical trial matching and clinical research workflows. The designation gives Massive Bio a formal role within OpenAI’s partner ecosystem as it scales AI tools for health systems, research networks, biopharmaceutical companies and patient-support organizations.

Massive Bio’s platform uses AI to convert complex clinical trial eligibility criteria into structured, machine-readable parameters and combines clinical and biomarker data to identify potential trial options for patients. The company plans to expand its OpenAI-related offerings while investing in talent and training, with human oversight and performance evaluation remaining part of its deployment approach.

For clinicians and patients, the partnership could support faster trial identification and reduce manual screening work. It also reflects growing use of generative AI to streamline complex oncology research and patient-access workflows.

前往原文 ↗